Spring Valley Acquisition Corp. II - Rights Azioni (NASDAQ: SVIIR)

Ultime notizie per Spring Valley Acquisition Corp. II - Rights (NASDAQ:SVIIR) Azioni

Spring Valley Acquisition Corp. II - Rights

<a href="https://www.globenewswire.com/Tracker?data=ujq_6hN5qdiPiaJEdXs9wZMAS9tDH537lcjOSn9ntIp50gqk27EX0OpNdwmMULv6hbgmAxS-GUiOvjV6qSAGrdC842Ss7R21A0d_5gYytAY=">AIM ImmunoTech Inc.</a> (NYSE:<a href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>)&nbsp;("AIM" or the "Company") today announced that the strong clinical successes in oncology of its drug Ampligen will be presented in four separate aspects at the upcoming&nbsp;<a href="https://www.globenewswire.com/Tracker?data=Ri12Z_Rred1Z5OXBIUBLC03KCb8S4o8S6ljcwCbl9G0_6yzPMi8KLblTl86M5kTqjVKUcZcRmYYco_I-xPGhD0ohPkDlaBxDxzTTBPNc3Q5GYWkkq0n_95NRPxuielwGokyb3vrYWNty763Kxbq23IiWkhJooe3lo63-x3j0TLej9yYpXpbe-R-JQ1towTypUjd79Bk5h2xaTl3D-z9Ko740cM6IcGR9SkavIxmjkm1owUM1M54ndwhn1sKyjFXwSixh6qdqwh7jAdXmGtRW5i_uBRyKinPF3XuU28e5QQ0=">5th&nbsp;Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care</a> in Warsaw, Poland. This will include a presentation by AIM regarding its ongoing lead clinical program in late-stage pancreatic cancer; a presentation by Pawel Kalinski, MD, PhD, a world-renowned research oncologist and senior investigator for multiple oncology clinical studies involving Ampligen, outlining his clinical research with Ampligen in multiple other solid tumor types; a presentation of Kathleen Kokolus, PhD, a senior scientist in Dr. Kalinski' laboratory, who will discuss cellular and molecular mechanisms of action of Ampligen; and finally a presentation and abstract on positive data strongly suggesting Ampligen's potential as a therapy in the treatment of endometriosis.
Dr. Kalinski observed, "This important global symposium is being held September 3-5, 2025. It will be attended by many of the top oncology researchers, government health officials and major pharma companies of Europe, in an effort to showcase and bring U.S.-developed, early-phase clinical trials to patients in Central and Eastern European Countries (CEEC) and to accelerate the development and clinical testing of such treatments to benefit patients in the United States and worldwide."
Oncology
An AIM representative will present data from AIM's pancreatic cancer Early Access Program and advances in the Phase 2 pancreatic cancer clinical trial currently underway at Erasmus Medical Center in the Netherlands. Among the expected highlights will be recent data from the DURIPANC study, an ongoing Phase 2 clinical study evaluating the combination therapy of Ampligen and AstraZeneca's anti-PD-L1 immune checkpoint inhibitor durvalumab in the treatment of late-stage metastatic pancreatic cancer patients. Following FOLFIRINOX, maintenance or second-line immunotherapies have historically shown limited survival benefit in comparison trials. Preliminary data from DURIPANC suggests that Ampligen may prove to change that equation for the better.
Last week, the Company released a <a href="https://www.globenewswire.com/Tracker?data=rHhgCs-gms-lOuAeqIWnauQmCUVHQcF-5wUeo70t83ZFmEsOWKqD1Z2uUIA74IgDFS4Y42oxW3HPS6cceXKa3duRSZxUcyKcnjkrYLqeh_XtGZv-fk9D5w9YM8uFzYjtRzOUp9yKJ97dF5M3nyby3e0mqwGmzWe2ujhzHv2KwMMMhKpmZz_PzFH0eHLKjeceWQxK-tS2V0jyxX1wJD0ewDOjOgUyri92dpbNOcA57m5YcHrRV1H1ShKU33FX-dOT9tqB7N5HX9S-mndJ2r5s30uFgQRFqjRRMbEw8eFE1kdmp3LlFmpNnoIInRhlrNweCjaERR7UYJx276tNYIRZAdtHXOMsQ_A1MGZ3NqMwi1KM80BVGkA2FU1i304Bq9fdIkyvYKC1rNApuBTv6iLX5H5WvG9gD6pnKuUZlN_cN0mQztXIrE9Mc9Ewjt4edpT1">DURIPANC Mid-Year Interim Clinical Progress Update</a> showing that the therapy is, thus far, well-tolerated with positive preliminary survival data, especially given the historical difficulty of improving outcomes in this setting.&nbsp;Compared to historical data, the DURIPANC study mid-year report shows continuing promising early signs of both no significant toxicity and superior PFS and OS:
<ul>
<li>No significant toxicity, an encouraging safety profile for a post-chemo setting;</li>
<li>~21% of patients have PFS &gt;6 months (3/14), with an additional 21% not yet progressed; and</li>
<li>OS &gt;6 months in the majority (64%) of eligible patients-better than expected in this setting.</li>
</ul>

Biotech

News

General

Aim Immunotech Announces That Its Drug Ampligen Will Be Featured In Four Presentations At Upcoming 5th Annual Marie Sklodowska-Curie Symposium On Cancer Research And Care In Warsaw, Poland

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.logprostyle.co.jp%2F&amp;esheet=54303947&amp;newsitemid=20250806317698&amp;lan=en-US&amp;anchor=LogProstyle+Inc.&amp;index=1&amp;md5=6848faf49572e51f189cf61650e9851b">LogProstyle Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LGPS#NYSE">LGPS</a>) (the "Company" or "LogProstyle"), headquartered in Minato-ku, Tokyo, Japan, is pleased to announce that on July 28, 2025, the Company entered into a shareholders' agreement with Australia-based Inmark Global Pty Ltd. ("Inmark") to establish a joint venture entity, Inmark LogProstyle Co., Ltd. ("Inmark LogProstyle"). The parties agreed to an initial ownership ratio whereby Inmark will subscribe for a 51% interest and LogProstyle will subscribe for a 49% interest in the company. Inmark LogProstyle plans to originate, acquire, finance, develop, manage, operate, and enhance real estate investment assets across Japan, with a particular emphasis on the multi-family real estate sector.

Contracts

Global

LGPS

LogProstyle And Inmark Form Joint Venture, Inmark Holds 51% And LogProstyle 49% Ownership, To Develop Multi-Family Real Estate In Japan

7AI And DXC Technology Partnership To Launch DXC Agentic Security Operations Center

Multi-year renewal extends Affirm's exclusive role as Boot Barn's pay-over-time provider, both online and in-store
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bootbarn.com%2F&amp;esheet=54303395&amp;newsitemid=20250806125694&amp;lan=en-US&amp;anchor=Boot+Barn+Holdings%2C+Inc.&amp;index=1&amp;md5=af92f429c57b9a2cc5ba83e6425bc247">Boot Barn Holdings, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>), the parent company of Boot Barn, Sheplers, and Country Outfitter, today announced it has extended its exclusive, multi-year partnership with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.affirm.com%2F&amp;esheet=54303395&amp;newsitemid=20250806125694&amp;lan=en-US&amp;anchor=Affirm&amp;index=2&amp;md5=3025f5be06acfc73ba7f5df00db1a3dd">Affirm</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>), the payment network that empowers consumers and helps merchants drive growth. The renewed agreement builds on a strong relationship between the two companies, allowing consumers to continue using Affirm to pay over time — both online at checkout across all three brands and in-store at over 450 Boot Barn locations nationwide.
Whether shopping for work boots, western wear, or apparel and home goods, paying with Affirm is simple. In-store, consumers just open the Affirm app, search for "Boot Barn," and tap "Shop in Store" to get started. Online, they simply choose Affirm at checkout. In both cases, consumers go through a quick eligibility check and, if approved, are offered customized biweekly or monthly payment plans starting at 0% APR and options up to 24 months. As always with Affirm, consumers will never pay late or hidden fees, ever.

AFRM

BOOT

Boot Barn Holdings Extends Exclusive, Multi-Year Partnership With Affirm Allowing Consumers To Continue Using Affirm To Pay Over Time

Media

Disney Says Co Is Developing Original Property Under The 20th Century And Searchlight Banner

WIIM

GSM stock has given up its prior gain. Ferroglobe shares were trading higher after the company reported a Q2 adjusted EPS miss.

In the preceding three months, 8 analysts have released ratings for Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $10.12, along with a high estimate of $12.00 and a low estimate of $8.50. Witnessing a positive shift, the current average has risen by 3.16% from the previous average price target of $9.81.
<img src="https://www.benzinga.com/files/images/story/2025/1754485382_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of Snap by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.50</td>
<td>$10.00</td>
</tr>
<tr>
<td>Mark Shmulik</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$10.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Brian Nowak</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$8.50</td>
<td>$6.50</td>
</tr>
<tr>
<td>Lloyd Walmsley</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>John Blackledge</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$10.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$11.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Rob Sanderson</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$16.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Snap. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Snap compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Snap's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SNAP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Snap analyst ratings.</a>
<h2>About Snap</h2>
Snap is a technology company best known for its marquis social media application Snapchat, a visual messaging application that has amassed hundreds of millions of users. The app was initially only used to communicate with family and friends through photographs and short videos (known as "Snaps"). Users can now enjoy augmented reality, or AR, lenses, content from famous creators and celebrities, updates about local events, and more. Although the app offers a paid subscription option with premium features, advertising sales produce most of the app's revenue. The firm also sells wearable devices called AR Spectacles, which can capture photos and videos overlayed with AR lenses, but these make up a small portion of Snap's overall sales.
<h3>Snap's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, Snap showcased positive performance, achieving a revenue growth rate of 14.1% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Communication Services sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Snap's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -10.24%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Snap's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -5.86%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Snap's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.8%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.82, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

SNAP

The Analyst Verdict: Snap In The Eyes Of 8 Experts

CPAY

CRCL

Corpay And Circle Announce Collaboration To Expand Stablecoin Access

Solitario Zinc (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/XPL#AMEX">XPL</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.02) by 50 percent. This is unchanged from the same period last year.

Earnings

Earnings Beats

Solitario Zinc Q2 EPS $(0.01) Beats $(0.02) Estimate

<a href="https://www.globenewswire.com/Tracker?data=WcHiKCCnJT-63BkzIWwj4bgrbKuxRr9iW0U0IpKFdeHFT2pFhPZohl0ymW1KcCxYCrwREpCXYpQUA5hcteG2Vw==">Femasys Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its first commercial entry into Europe with an order of approximately $400,000 USD for FemBloc Permanent Birth Control in Spain, the first country with an established distribution partnership.
"We are proud to be executing on our mission to expand access to FemBloc, an innovative, non-surgical solution and the only advancement in permanent birth control that offers a less invasive alternative to current and formerly available methods," said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys Inc. "To support that mission, we selected our partners in Spain, Comercial Medico Quirúrgica and Durgalab, based on their successful track record commercializing complex women's health technologies like Essure&nbsp;permanent contraceptive (originally by Conceptus and later acquired by Bayer). Their expertise and provider relationships make them ideal collaborators to introduce FemBloc, which will first become available in Spain, the first country in the world to offer access to this groundbreaking option. With a growing backlog of FemBloc product, we are focused on scaling production to meet anticipated demand as interest builds across Europe."

FEMY

Femasys Secures First Commercial Entry Into Europe With An Order Of ~$400K For FemBloc Permanent Birth Control In Spain

Zebra Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>) posted better-than-expected second-quarter earnings and <a href="https://www.benzinga.com/quote/ZBRA/earnings">raised its FY 2025 adjusted EPS guidance above estimates.</a>
Zebra Technologies posted adjusted earnings of $3.61 per share, beating market estimates of $3.31 per share. The company's sales came in-line with estimates at $1.29 billion.
Zebra Technologies raised its FY2025 adjusted EPS guidance from $13.75-$14.75 to $15.25-$15.75 and narrowed sales guidance from $5.13 billion-$5.33 billion to $5.23 billion-$5.33 billion.
&#8220;Solid demand, excellent execution by our team and lower-than-expected tariffs enabled us to deliver second quarter results that exceeded our expectations,&#8221; said Bill Burns, Chief Executive Officer of Zebra Technologies. &#8220;We are raising both our sales and profitability outlook for the full year, given our solid first half results and expectation for second half growth. Looking ahead, we are focused on driving shareholder value and advancing our industry leadership with our innovative solutions that digitize and automate our customers&#8217; workflows.&#8221;
Zebra Technologies shares fell 11.4% to close at $302.60 on Tuesday.
These analysts made changes to their price targets on Zebra Technologies following earnings announcement.
<ul class="wp-block-list">
<li>Needham analyst James Ricchiuti maintained Zebra Technologies with a Buy and raised the price target from $325 to $345.</li>
<li>Truist Securities analyst Jamie Cook maintained Zebra Technologies with a Hold and raised the price target from $269 to $319.</li>
</ul>
Considering buying ZBRA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/06090024/image-105-1024x583.png" alt="" class="wp-image-1016949" style="width:656px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/06090024/image-105-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/06090024/image-105-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/06090024/image-105-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/06090024/image-105.png 1146w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/08/46856530/top-2-health-care-stocks-you-may-want-to-dump-in-q3">Top 2 Health Care Stocks You May Want To Dump In Q3</a></li>
</ul>
Photo via Shutterstock

Price Target

Pre-Market Outlook

Markets

Trading Ideas

ZBRA

These Analysts Boost Their Forecasts On Zebra Technologies After Upbeat Earnings

4 analysts have shared their evaluations of Cardiff Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $12.62, a high estimate of $19.00, and a low estimate of $3.50. Observing a downward trend, the current average is 27.89% lower than the prior average price target of $17.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1754485339_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Cardiff Oncology among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Kevin DeGeeter</td>
<td>Ladenburg Thalmann</td>
<td>Announces</td>
<td>Buy</td>
<td>$19.00</td>
<td>-</td>
</tr>
<tr>
<td>Maury Raycroft</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$3.50</td>
<td>-</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Cardiff Oncology. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cardiff Oncology compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Cardiff Oncology's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Cardiff Oncology's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CRDF/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Cardiff Oncology analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Cardiff Oncology</h2>
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
<h3>Unraveling the Financial Story of Cardiff Oncology</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Cardiff Oncology's financials over 3M reveals challenges. As of 30 June, 2025, the company experienced a decline of approximately -25.77% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Cardiff Oncology's net margin excels beyond industry benchmarks, reaching -11528.1%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Cardiff Oncology's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -21.55%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Cardiff Oncology's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -17.38%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.02.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CRDF

A Glimpse Into The Expert Outlook On Cardiff Oncology Through 4 Analysts

First Horizon's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>) short percent of float has fallen 17.92% since its last report. The company recently reported that it has 10.92 million shares sold short, which is 2.84% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.86 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>First Horizon Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1754485337_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for First Horizon has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing First Horizon's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, First Horizon's peer group average for short interest as a percentage of float is 4.16%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What's Driving the Market Sentiment Around First Horizon?

Macquarie analyst Steve Koenig maintains Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) with a Neutral and maintains $37 price target.

KVYO

Macquarie Maintains Neutral on Klaviyo, Maintains $37 Price Target

Ascendis Pharma's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NYSE">ASND</a>) short percent of float has risen 20.44% since its last report. The company recently reported that it has 2.73 million shares sold short, which is 5.42% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.11 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Ascendis Pharma Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1754485332_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ascendis Pharma has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ascendis Pharma's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Ascendis Pharma's peer group average for short interest as a percentage of float is 5.99%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ASND

What's Driving the Market Sentiment Around Ascendis Pharma?

In the preceding three months, 12 analysts have released ratings for Toast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Toast, revealing an average target of $49.5, a high estimate of $60.00, and a low estimate of $37.00. Observing a 10.24% increase, the current average has risen from the previous average price target of $44.90. 
<img src="https://www.benzinga.com/files/images/story/2025/1754485331_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Toast is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$50.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Josh Baer</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Peter Heckmann</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$46.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Samad Samana</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$54.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Matthew Coad</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Nate Svensson</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$54.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Coad</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$48.00</td>
<td>-</td>
</tr>
<tr>
<td>Rufus Hone</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Josh Baer</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$46.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Toast. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Toast compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Toast's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Toast's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TOST/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Toast analyst ratings.</a>
<h2>About Toast</h2>
Toast is an end-to-end technology platform designed to address the complex needs of the restaurant industry. The company generates point-in-time revenue through sales of its restaurant-grade hardware and recurring revenue in the form of take rates on restaurant transaction volume as well as subscriptions to its software solutions. As of fiscal 2024, the company provided services to 134,000 restaurant locations primarily in the US. Toast's typical customer is a mid-market restaurant generating slightly more than $1 million in revenue annually.
<h3>Toast: Delving into Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Toast's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 24.37%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Toast's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 4.19%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Toast's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 3.48%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Toast's ROA excels beyond industry benchmarks, reaching 2.25%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.01, Toast adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TOST

12 Analysts Have This To Say About Toast

Golden Matrix Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMGI#NASDAQ">GMGI</a>) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.01) by 500 percent. The company reported quarterly sales of $43.245 million which missed the analyst consensus estimate of $44.814 million by 3.50 percent. This is a 9.72 percent increase over sales of $39.415 million the same period last year.

Earnings Misses

GMGI

Golden Matrix Group Q2 EPS $(0.03) Misses $(0.01) Estimate, Sales $43.245M Miss $44.814M Estimate

Honeywell Intl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HON#NYSE">HON</a>) short percent of float has fallen 15.32% since its last report. The company recently reported that it has 6.64 million shares sold short, which is 1.05% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.43 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Honeywell Intl Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1754485326_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Honeywell Intl has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Honeywell Intl's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Honeywell Intl's peer group average for short interest as a percentage of float is 6.79%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is Honeywell Intl Gaining or Losing Market Support?

4 analysts have expressed a variety of opinions on Advanced Energy Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEIS#NASDAQ">AEIS</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $148.75, a high estimate of $160.00, and a low estimate of $130.00. This current average reflects an increase of 13.33% from the previous average price target of $131.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1754485322_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Advanced Energy Indus. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$155.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Brian Chin</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Ken Newman</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Joe Quatrochi</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$130.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Advanced Energy Indus. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Advanced Energy Indus compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Advanced Energy Indus's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Advanced Energy Indus's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AEIS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Advanced Energy Indus analyst ratings.</a>
<h2>About Advanced Energy Indus</h2>
Advanced Energy Industries Inc provides precision power-conversion measurement and control solutions that transform power into various forms for use in manufacturing and industrial equipment and applications. The firm serves original equipment manufacturers and end customers in the semiconductor, flat panel display, solar panel, and other industrial capital equipment markets. Products include thin-film power-conversion systems, which control and modify raw electrical power into a customizable, predictable power source, and power control modules, which control and measure temperature during manufacturing cycles. A majority of the firm's revenue is generated in United States, with the rest from Mexico, Taiwan, China and All others.
<h3>Financial Insights: Advanced Energy Indus</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Advanced Energy Indus's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 23.54%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: Advanced Energy Indus's net margin is impressive, surpassing industry averages. With a net margin of 6.1%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Advanced Energy Indus's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.03%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Advanced Energy Indus's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.08% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Advanced Energy Indus's debt-to-equity ratio surpasses industry norms, standing at 0.55. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEIS

Demystifying Advanced Energy Indus: Insights From 4 Analyst Reviews

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fabout.gitlab.com%2F&amp;esheet=54303317&amp;newsitemid=20250806904416&amp;lan=en-US&amp;anchor=GitLab+Inc.&amp;index=1&amp;md5=9a3c4f801f85a4c98aa0f58ad62f462b">GitLab Inc.</a>, the most comprehensive, intelligent DevSecOps platform, announced today that it has signed a three-year, strategic collaboration agreement (SCA) with Amazon Web Services (AWS).
The agreement expands access to GitLab Dedicated, a single-tenant offering that enables organizations in highly regulated industries and the public sector to leverage cloud infrastructure while meeting complex compliance requirements, including data residency, isolation, and private networking.

Comments

Spring Valley Acquisition Corp. II - Rights

Notizie

Ultime notizie per Spring Valley Acquisition Corp. II - Rights (NASDAQ:SVIIR) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO